Pharmaceutical-grade peptides & lab-use compounds available online.
Free US shipping for orders above $600
Skip to content Pharmaceutical-grade peptides & lab-use compounds available online.
Free US shipping for orders above $600
This product is intended solely for use as a research chemical in vitro and laboratory experimentation by licensed, qualified professionals.
Tirzepatide is the first dual receptor agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). In May 2022, the FDA approved tirzepatide for the treatment of type 2 diabetes. In November 2023, tirzepatide was approved for the treatment of obesity. In 2024, it was approved to improve the symptoms of obese patients with obstructive sleep apnea (OSA), becoming the first prescription drug in the world for this indication.
| Specifications | Price |
|---|---|
| 1g | $1.00 |
| 10g | $10.00 |
| 1000g | $1,000.00 |
HPLS
Testing
Endotoxin
Assay
TAMC
Test
TYMC
Test
Heavy Metal
Screening
| Property | Details | ||||||
|---|---|---|---|---|---|---|---|
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈·XNa | ||||||
| Molecular Weight | 4813.45 g/mol | ||||||
| CAS Number | 2023788-19-2 | ||||||
| Appearance | White Powder | ||||||
| Storage Conditions | |||||||
| |||||||
By simultaneously activating the GLP-1 and GIP receptor signaling pathways, it reduces appetite and increases energy expenditure. Its dual-target mechanism can produce a synergistic effect, and is more effective in weight loss compared to single-target drugs.
Antidiabetic effect: In multiple phase III clinical trials (such as the SURPASS series of studies), tesiprime demonstrated better antidiabetic effects than other GLP-1 single receptor agonists (such as semaglutide) and basal insulin. Some patients achieved a reduction in glycated hemoglobin (HbA1c) of more than 2%, making it the best GLP-1 receptor agonist drug for controlling blood sugar.
Weight loss effect: Patients lost an average of 10%-15% of their weight, significantly more than traditional antidiabetic drugs, and the effect was dose-dependent.
Cardiovascular and metabolic benefits: Studies suggest that it may improve metabolic indicators such as blood lipids and blood pressure, reduce severity, and lower the risk of cardiovascular diseases.
SURMOUNT-1/2 trial (2022): The highest dose group (15 mg) achieved an average weight loss of approximately 43.5 pounds (about 21.75 kg), and nearly one-third of the subjects lost more than 52.6 pounds (25% of body weight).
SURMOUNT-OSA trial (2024): Patients not receiving positive pressure ventilation treatment had a reduction of 25 breath interruptions per hour, and 42% of patients experienced symptom relief to mild.
Head-to-head study (December 2024): Compared to semaglutide, it achieved 1.47 times the relative weight loss, with an absolute weight loss ratio of 20.2% vs 13.7%.
All product is sold solely for scientific research purposes. Researchers are responsible for ensuring compliance with local regulations and institutional guidelines. Keep out of reach of children and unauthorized personnel.
1688pharma is more than just a trusted supplier of research peptides. We are committed to scientific advancement, dedicated to providing the highest quality pharmaceutical-grade compounds that empower researchers and clients to achieve their goals.
Our proprietary processes and meticulous sourcing of premium materials ensure that every peptide we offer meets the most stringent pharmaceutical standards with verified 99% purity.
Every peptide undergoes rigorous third-party laboratory testing using advanced techniques like HPLC, LC-MS, and NMR. Complete Certificates of Analysis available for transparency and verification.
We provide expedited worldwide shipping with reliable tracking and discreet packaging. Our dedicated customer support team assists with orders, storage guidelines, and product inquiries promptly.
